OR WAIT 15 SECS
The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.
Cambrex announced on Nov. 17, 2020 that it is investing more than $50 million into the expansion of its mid-scale and large-scale API manufacturing capacity in Charles City, IA.
Set to be operational by early 2022, the expansion will add three large-scale manufacturing work centers and a mid-scale work center to the facility, increasing its capacity by 30%, and giving Cambrex the opportunity to employ more than 400 people at the site, a company press release said. The expansion will be designed to meet the growing demand for small molecule drug substance development and manufacturing.
“Small molecule manufacturing demand has been growing consistently over recent years, and this investment will enable Cambrex to continue to capitalize on this growth, further strengthening our position as a market-leading CDMO,” said Joe Nettleton, president of Cambrex’s Drug Substance Business Unit, in the press release. “This expansion in the US for API manufacturing capacity comes at a time when our customers increasingly require high-quality partners to ensure reliable supply chains within the pharmaceutical sector.”